Sustainable financing has grown in popularity in recent years, as more institutional investors and funds incorporate Environmental, Social and Governance (ESG) investing tactics. Thus, those wishing to participate in the biopharma revolution must prepare to answer for their companies’ ESG impact to capture investment capital and prepare for potential new regulatory requirements.

This session will detail ESG challenges for biopharma companies and offer proven strategies for effective communication with ESG-focused investors. Points of discussion will include:

• What are the greatest ESG risks biopharma companies are facing?
• Why is it important for biopharma companies to understand their ESG risk exposure?
• How do you provide clarity and transparency to stakeholders on sustainability attributes?